What can we expect from the serotonergic side of l-DOPA?;Que pouvons-nous attendre de la composante sérotoninergique de la l-DOPA ?

Revue Neurologique

Volumn 168, Issue 12, 2012, Pages 927-938

  De Deurwaerdere P ^a   Navailles, S ^a  

^a CNRS   (France)

Author keywords

Dopamine; l DOPA; Parkinson's disease; Serotonin

Indexed keywords

DOPAMINE; LEVODOPA; RASAGILINE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; DRUG MECHANISM; HUMAN; NERVE CELL; NEUROTRANSMISSION; NONHUMAN; SEROTONINERGIC SYSTEM;

EID: 84870678166     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2012.01.585     Document Type: Review

References (111)

1. E.D. Abercrombie, A.E. Bonatz, and M.J. Zigmond Effects of l-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats Brain Res 525 1990 36 44
2. J.E. Ahlskog, and M.D. Muenter Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature Mov Disord 16 2001 448 458
3. B. Amilhon, E. Lepicard, T. Renoir, R. Mongeau, D. Popa, and O. Poirel VGLUT3 (vesicular glutamate transporter type 3) contribution to the regulation of serotonergic transmission and anxiety J Neurosci 30 2010 2198 2210
4. R. Arai, N. Karasawa, M. Geffard, and I. Nagatsu l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study Neurosci Lett 195 1995 195 198
5. W. Bara-Jimenez, F. Bibbiani, M.J. Morris, T. Dimitrova, A. Sherzai, and M.M. Mouradian Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease Mov Disord 20 2005 932 936
6. P. Barone, L. Scarzella, R. Marconi, A. Antonini, L. Morgante, and F. Bracco Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study J Neurol 253 2006 601 607
7. P. Barone, W. Poewe, S. Albrecht, C. Debieuvre, D. Massey, and O. Rascol Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial Lancet Neurol 9 2010 573 580
8. A. Berthet, and E. Bezard Dopamine receptors and l-DOPA-induced dyskinesia Parkinsonism Relat Disord 15 SUPPL 4 2009 S8 S12
9. A. Berthet, and E. Bezard GRK6, a new therapeutic approach to alleviate l-DOPA-induced dyskinesia Med Sci (Paris) 26 2010 800 803
10. F. Bibbiani, J.D. Oh, and T.N. Chase Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models Neurology 57 2001 1829 1834
11. C.S. Biggs, and M.S. Starr Dopamine and glutamate control each other's release in the basal ganglia: a microdialysis study of the entopeduncular nucleus and substantia nigra Neurosci Biobehav Rev 21 1997 497 504
12. C. Bishop, D.M. Krolewski, K.L. Eskow, C.J. Barnum, K.B. Dupre, and T. Deak Contribution of the striatum to the effects of 5-HT1A receptor stimulation in l-DOPA-treated hemiparkinsonian rats J Neurosci Res 87 2009 1645 1658
13. C. Bishop, J.L. Taylor, D.M. Kuhn, K.L. Eskow, J.Y. Park, and P.D. Walker MDMA and fenfluramine reduce l-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation Eur J Neurosci 23 2006 2669 2676
14. V. Bonifati, E. Fabrizio, R. Cipriani, N. Vanacore, and G. Meco Buspirone in levodopa-induced dyskinesias Clin Neuropharmacol 17 1994 73 82
15. R. Bordet Central dopamine receptors: general considerations (Part 1) Rev Neurol (Paris) 160 2004 862 870
16. H. Braak, K. Del Tredici, H. Bratzke, J. Hamm-Clement, D. Sandmann-Keil, and U. Rub Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages) J Neurol 249 SUPPL 3 2002 III/1 III/5
17. E.S. Bromberg-Martin, O. Hikosaka, and K. Nakamura Coding of task reward value in the dorsal raphe nucleus J Neurosci 30 2010 6262 6272
18. E.S. Bromberg-Martin, M. Matsumoto, and O. Hikosaka Dopamine in motivational control: rewarding, aversive, and alerting Neuron 68 2010 815 834
19. W.D. Brown, M.D. Taylor, A.D. Roberts, T.R. Oakes, M.J. Schueller, and J.E. Holden FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa Neurology 53 1999 1212 1218
20. B.S. Bunney, G.K. Aghajanian, and R.H. Roth Comparison of effects of l-DOPA, amphetamine and apomorphine on firing rate of rat dopaminergic neurones Nat New Biol 245 1973 123 125
21. P. Calabresi, P. Gubellini, D. Centonze, B. Picconi, G. Bernardi, and K. Chergui Dopamine and cAMP-regulated phosphoprotein 32kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity J Neurosci 20 2000 8443 8451
22. M. Carlsson, and A. Carlsson Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease Trends Neurosci 13 1990 272 276
23. M. Carta, T. Carlsson, D. Kirik, and A. Bjorklund Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats Brain 130 2007 1819 1833
24. M. Carta, T. Carlsson, A. Munoz, D. Kirik, and A. Bjorklund Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease Mov Disord 25 SUPPL 1 2010 S174 S179
25. M.A. Cenci Transcription factors involved in the pathogenesis of l-DOPA-induced dyskinesia in a rat model of Parkinson's disease Amino Acids 23 2002 105 109
26. M.A. Cenci, and K.E. Ohlin Rodent models of treatment-induced motor complications in Parkinson's disease Parkinsonism Relat Disord 15 SUPPL 4 2009 S13 S17
27. T.N. Chase Levodopa therapy: consequences of the non-physiologic replacement of dopamine Neurology 50 1998 S17 S25
28. G.C. Cotzias l-DOPA for Parkinsonism N Engl J Med 278 1968 630
29. G.C. Cotzias, P.S. Papavasiliou, and R. Gellene Modification of Parkinsonism - chronic treatment with l-DOPA N Engl J Med 280 1969 337 345
30. P. De Deurwaerdère Aspects physiologiques et physiopathologiques de la transmission sérotoninergique au sein des ganglions de la base D.O. Varoquaux-Spreux, La sérotonine 2011 Editions Lavoisier
31. R. de la Fuente-Fernandez, V. Sossi, Z. Huang, S. Furtado, J.Q. Lu, and D.B. Calne Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias Brain 127 2004 2747 2754
32. C. Delaville, P.D. Deurwaerdere, and A. Benazzouz Noradrenaline and Parkinson's disease Front Syst Neurosci 5 2011 31
33. C. Delaville, J. Chetrit, K. Abdallah, S. Morin, L. Cardoit, and P. De Deurwaerdère Emerging dysfunctions consequent to multiple monoaminergic depletions in experimental parkinsonism Neurobiol Dis 45 2012 763 773
34. V. Di Matteo, M. Pierucci, E. Esposito, G. Crescimanno, A. Benigno, and G. Di Giovanni Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders Prog Brain Res 172 2008 423 463
35. K.B. Dupre, K.L. Eskow, G. Negron, and C. Bishop The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat Brain Res 1158 2007 135 143
36. F. Durif, M. Vidailhet, A.M. Bonnet, J. Blin, and Y. Agid Levodopa-induced dyskinesias are improved by fluoxetine Neurology 45 1995 1855 1858
37. U. Ehrt, K. Bronnick, A.F. Leentjens, J.P. Larsen, and D. Aarsland Depressive symptom profile in Parkinson's disease: a comparison with depression in elderly patients without Parkinson's disease Int J Geriatr Psychiatry 21 2006 252 258
38. K.L. Eskow Jaunarajs, M. Angoa-Perez, D.M. Kuhn, and C. Bishop Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment Neurosci Biobehav Rev 35 2011 556 564
39. K.L. Eskow, K.B. Dupre, C.J. Barnum, S.O. Dickinson, J.Y. Park, and C. Bishop The role of the dorsal raphe nucleus in the development, expression, and treatment of l-DOPA-induced dyskinesia in hemiparkinsonian rats Synapse 63 2009 610 620
40. S. Fahn, L.R. Libsch, and R.W. Cutler Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor J Neurol Sci 14 1971 427 455
41. S.H. Fox, R. Chuang, and J.M. Brotchie Serotonin and Parkinson's disease: on movement, mood, and madness Mov Disord 24 2009 1255 1266
42. C.G. Goetz, P. Damier, C. Hicking, E. Laska, T. Muller, and C.W. Olanow Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial Mov Disord 22 2007 179 186
43. J. Gumpert, D. Sharpe, and G. Curzon Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa J Neurol Sci 19 1973 1 12
44. D.G. Harden, and A.A. Grace Activation of dopamine cell firing by repeated l-DOPA administration to dopamine-depleted rats: its potential role in mediating the therapeutic response to l-DOPA treatment J Neurosci 15 1995 6157 6166
45. F. Hefti, E. Melamed, and R.J. Wurtman The site of dopamine formation in rat striatum after l-DOPA administration J Pharmacol Exp Ther 217 1981 189 197
46. A.S. Hollister, G.R. Breese, and R.A. Mueller Role of monoamine neural systems in L-dihydroxyphenylalanine-stimulated activity J Pharmacol Exp Ther 208 1979 37 43
47. O. Hornykiewicz Dopamine (3-hydroxytyramine) and brain function Pharmacol Rev 18 1966 925 964
48. O. Hornykiewicz Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of l-DOPA) Br Med Bull 29 1973 172 178
49. M.M. Iravani, M.J. Jackson, M. Kuoppamaki, L.A. Smith, and P. Jenner 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated primates J Neurosci 23 2003 9107 9115
50. M.M. Iravani, K. Tayarani-Binazir, W.B. Chu, M.J. Jackson, and P. Jenner In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability J Pharmacol Exp Ther 319 2006 1225 1234
51. K.A. Jellinger Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway Mol Chem Neuropathol 14 1991 153 197
52. P. Jenner, M. Sheehy, and C.D. Marsden Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease Br J Clin Pharmacol 15 SUPPL 2 1983 277S 289S
53. K. Kannari, H. Tanaka, T. Maeda, M. Tomiyama, T. Suda, and M. Matsunaga Reserpine pretreatment prevents increases in extracellular striatal dopamine following l-DOPA administration in rats with nigrostriatal denervation J Neurochem 74 2000 263 269
54. K. Kannari, H. Yamato, H. Shen, M. Tomiyama, T. Suda, and M. Matsunaga Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered l-DOPA in the striatum with nigrostriatal denervation J Neurochem 76 2001 1346 1353
55. S.J. Kish, J. Tong, O. Hornykiewicz, A. Rajput, L.J. Chang, and M. Guttman Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease Brain 131 2008 120 131
56. V. Kiyasova, S.P. Fernandez, J. Laine, L. Stankovski, A. Muzerelle, and S. Doly A genetically defined morphologically and functionally unique subset of 5-HT neurons in the mouse raphe nuclei J Neurosci 31 2011 2756 2768
57. J. Korf, H.M. van Praag, D. Schut, R.J. Nienhuis, and J.P. Lakke Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for l-DOPA therapy Eur Neurol 12 1974 340 350
58. W.L. Kuan, J.W. Zhao, and R.A. Barker The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram Psychopharmacology (Berl) 197 2008 279 293
59. H.S. Lindgren, D.R. Andersson, S. Lagerkvist, H. Nissbrandt, and M.A. Cenci l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia J Neurochem 112 2010 1465 1476
60. K. Lloyd, and O. Hornykiewicz Parkinson's disease: activity of l-DOPA decarboxylase in discrete brain regions Science 170 1970 1212 1213
61. A. Lopez, A. Munoz, M.J. Guerra, and J.L. Labandeira-Garcia Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum Neuroscience 103 2001 639 651
62. T. Maeda, K. Kannari, T. Suda, and M. Matsunaga Loss of regulation by presynaptic dopamine D2 receptors of exogenous l-DOPA-derived dopamine release in the dopaminergic denervated striatum Brain Res 817 1999 185 191
63. S.A. Mandel, Y. Sagi, and T. Amit Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway Neurochem Res 32 2007 1694 1699
64. C. Marin, E. Aguilar, M.C. Rodriguez-Oroz, G.D. Bartoszyk, and J.A. Obeso Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats Psychopharmacology (Berl) 204 2009 241 250
65. M. Marti, C. Trapella, R. Viaro, and M. Morari The nociceptin/orphanin FQ receptor antagonist J-113397 and l-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway J Neurosci 27 2007 1297 1307
66. W. Meissner, P. Ravenscroft, R. Reese, D. Harnack, R. Morgenstern, and A. Kupsch Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine Neurobiol Dis 22 2006 586 598
67. E. Melamed, F. Hefti, J. Liebman, A.J. Schlosberg, and R.J. Wurtman Serotonergic neurones are not involved in action of l-DOPA in Parkinson's disease Nature 283 1980 772 774
68. N.B. Mercuri, P. Calabresi, and G. Bernardi Responses of rat substantia nigra compacta neurones to l-DOPA Br J Pharmacol 100 1990 257 260
69. D.W. Miller, and E.D. Abercrombie Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous l-DOPA: studies in intact and 6-hydroxydopamine-treated rats J Neurochem 72 1999 1516 1522
70. M.E. Molliver Serotonergic neuronal systems: what their anatomic organization tells us about function J Clin Psychopharmacol 7 1987 3S 23S
71. A. Munoz, Q. Li, F. Gardoni, E. Marcello, C. Qin, and T. Carlsson Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia Brain 131 2008 3380 3394
72. K. Nakamura, M. Ahmed, E. Barr, J.M. Leiden, and U.J. Kang The localization and functional contribution of striatal aromatic L-amino acid decarboxylase to L-3,4-dihydroxyphenylalanine decarboxylation in rodent parkinsonian models Cell Transplant 9 2000 567 576
73. K. Nakamura, M. Matsumoto, and O. Hikosaka Reward-dependent modulation of neuronal activity in the primate dorsal raphe nucleus J Neurosci 28 2008 5331 5343
74. S. Navailles, A. Benazzouz, B. Bioulac, C. Gross, and P. De Deurwaerdere High-frequency stimulation of the subthalamic nucleus and l-3,4- dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease J Neurosci 30 2010 2356 2364
75. S. Navailles, B. Bioulac, C. Gross, and P. De Deurwaerdere Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease Neurobiol Dis 38 2010 136 143
76. S. Navailles, B. Bioulac, C. Gross, and P. De Deurwaerdere Chronic l-DOPA therapy alters central serotonergic function and l-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease Neurobiol Dis 41 2011 585 590
77. S. Navailles, and P. De Deurwaerdère Presynaptic control of serotonin on striatal dopamine function Psychopharmacology (Berl) 213 2-3 2011 213 242
78. S. Navailles, and P. De Deurwaerdère Imbalanced dopaminergic transmission mediated by serotonergic neurons in l-DOPA-induced dyskinesia Parkinson's Dis 2012 2012 323686
79. L. Nègre-Pagès, H. Grandjean, M. Lapeyre-Mestre, J.L. Montastruc, A. Fourrier, and J.P. Lépine Anxious and depressive symptoms in Parkinson's disease: the French cross-sectionnal DoPaMiP study Mov Disord 25 2010 157 166
80. K.Y. Ng, T.N. Chase, R.W. Colburn, and I.J. Kopin l-DOPA-induced release of cerebral monoamines Science 170 1970 76 77
81. J.A. Obeso, C. Marin, C. Rodriguez-Oroz, J. Blesa, B. Benitez-Temino, and J. Mena-Segovia The basal ganglia in Parkinson's disease: current concepts and unexplained observations Ann Neurol 64 SUPPL 2 2008 S30 S46
82. C.W. Olanow, P. Damier, C.G. Goetz, T. Mueller, J. Nutt, and O. Rascol Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study) Clin Neuropharmacol 27 2004 58 62
83. D. Orosz, and J.P. Bennett Simultaneous microdialysis in striatum and substantia nigra suggests that the nigra is a major site of action of L-dihydroxyphenylalanine in the "hemiparkinsonian" rat Exp Neurol 115 1992 388 393
84. C.Y. Ostock, K.B. Dupre, K.L. Jaunarajs, H. Walters, J. George, and D. Krolewski Role of the primary motor cortex in l-DOPA-induced dyskinesia and its modulation by 5-HT1A receptor stimulation Neuropharmacology 61 2011 753 760
85. B. Picconi, A. Pisani, I. Barone, P. Bonsi, D. Centonze, and G. Bernardi Pathological synaptic plasticity in the striatum: implications for Parkinson's disease Neurotoxicology 26 2005 779 783
86. M. Politis, K. Wu, C. Loane, L. Kiferle, S. Molloy, and D.J. Brooks Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study Neurobiol Dis 40 2010 216 221
87. O. Rascol, D.J. Brooks, E. Melamed, W. Oertel, W. Poewe, and F. Stocchi Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial Lancet 365 2005 947 954
88. G.S. Robertson, and H.A. Robertson Evidence that l-DOPA-induced rotational behavior is dependent on both striatal and nigral mechanisms J Neurosci 9 1989 3326 3331
89. D. Rylander, M. Parent, S.S. O'Sullivan, S. Dovero, A.J. Lees, and E. Bezard Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia Ann Neurol 68 2010 619 628
90. S. Sarre, P. Herregodts, D. Deleu, A. Devrieze, N. De Klippel, and G. Ebinger Biotransformation of l-DOPA in striatum and substantia nigra of rats with a unilateral, nigrostriatal lesion: a microdialysis study Naunyn Schmiedebergs Arch Pharmacol 346 1992 277 285
91. S. Sarre, I. Smolders, K. Thorre, G. Ebinger, and Y. Michotte Biotransformation of locally applied precursors of dopamine, serotonin and noradrenaline in striatum and hippocampus: a microdialysis study J Neural Transm 104 1997 1215 1228
92. B. Scholtissen, F.R. Verhey, H.W. Steinbusch, and A.F. Leentjens Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data J Neural Transm 113 2006 59 73
93. A.G. Schuurman, M. van den Akker, K.T. Ensinck, J.F. Metsemakers, J.A. Knottnerus, and A.F. Leentjens Increased risk of Parkinson's disease after depression: a retrospective cohort study Neurology 58 2002 1501 1504
94. P. Seeman Brain dopamine receptors Pharmacol Rev 32 1980 229 313
95. M. Shiba, J.H. Bower, D.M. Maraganore, S.K. McDonnell, B.J. Peterson, and J.E. Ahlskog Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study Mov Disord 15 2000 669 677
96. J.J. Soghomonian l-DOPA-induced dyskinesia in adult rats with a unilateral 6-OHDA lesion of dopamine neurons is paralleled by increased c-fos gene expression in the subthalamic nucleus Eur J Neurosci 23 2006 2395 2403
97. S.E. Spencer, and G.F. Wooten Pharmacologic effects of l-DOPA are not closely linked temporally to striatal dopamine concentration Neurology 34 1984 1609 1611
98. Steinbusch HW. Serotonin-immunoreactive neurons and their projections in the CNS. In: Björklund AHT, Kuhar MJ, editors. Handbook of Chemical Neuroanatomy - Classical transmitters and transmitters receptors in the CNS Part II. Amsterdam: Elsevier; 1984. p. 68-125.
99. S.K. Tan, H. Hartung, T. Sharp, and Y. Temel Serotonin-dependent depression in Parkinson's disease: a role for the subthalamic nucleus? Neuropharmacology 61 2011 387 399
100. H. Tanaka, K. Kannari, T. Maeda, M. Tomiyama, T. Suda, and M. Matsunaga Role of serotonergic neurons in l-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats Neuroreport 10 1999 631 634
101. E. Tandberg, J.P. Larsen, D. Aarsland, and J.L. Cummings The occurrence of depression in Parkinson's disease. A community-based study Arch Neurol 53 1996 175 179
102. Y. Temel, L.J. Boothman, A. Blokland, P.J. Magill, H.W. Steinbusch, and V. Visser-Vandewalle Inhibition of 5-HT neuron activity and induction of depressive-like behavior by high-frequency stimulation of the subthalamic nucleus Proc Natl Acad Sci U S A 104 2007 17087 17092
103. F. Tison, N. Mons, M. Geffard, and P. Henry The metabolism of exogenous l-DOPA in the brain: an immunohistochemical study of its conversion to dopamine in non-catecholaminergic cells of the rat brain J Neural Transm Park Dis Dement Sect 3 1991 27 39
104. S. Tucci, R. Fernandez, T. Baptista, E. Murzi, and L. Hernandez Dopamine increase in the prefrontal cortex correlates with reversal of haloperidol-induced catalepsy in rats Brain Res Bull 35 1994 125 133
105. A. Ulusoy, G. Sahin, and D. Kirik Presynaptic dopaminergic compartment determines the susceptibility to l-DOPA-induced dyskinesia in rats Proc Natl Acad Sci U S A 107 2010 13159 13164
106. V. Voon, P.O. Fernagut, J. Wickens, C. Baunez, M. Rodriguez, and N. Pavon Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders Lancet Neurol 8 2009 1140 1149
107. O. Weinreb, T. Amit, O. Bar-Am, M.B. Youdim, and Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity Prog Neurobiol 92 2010 330 344
108. D. Weintraub, K.H. Morales, P.J. Moberg, W.B. Bilker, C. Balderston, and J.E. Duda Antidepressant studies in Parkinson's disease: a review and meta-analysis Mov Disord 20 2005 1161 1169
109. H. Yamato, K. Kannari, H. Shen, T. Suda, and M. Matsunaga Fluoxetine reduces l-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum Neuroreport 12 2001 1123 1126
110. B.Y. Zeng, M.M. Iravani, M.J. Jackson, S. Rose, A. Parent, and P. Jenner Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia Neurobiol Dis 40 2010 599 607
111. M.J. Zigmond, E.D. Abercrombie, T.W. Berger, A.A. Grace, and E.M. Stricker Compensations after lesions of central dopaminergic neurons: some clinical and basic implications Trends Neurosci 13 1990 290 296